Rein Therapeutics (RNTX) Current Leases (2019 - 2023)
Rein Therapeutics (RNTX) posted quarterly Current Leases of $48000.0 for Q4 2023, up 45.45% year-over-year from $33000.0 in Q4 2022, and up 45.45% quarter-over-quarter from $33000.0 in Q4 2022.
Rein Therapeutics (RNTX) Current Leases (2019 - 2023) Analysis & Trends
Rein Therapeutics (RNTX) has reported Current Leases for 5 consecutive years, with $48000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Current Leases rose 45.45% year-over-year to $48000.0; the TTM figure through Dec 2023 stood at $48000.0 (up 45.45% YoY), while the FY2023 annual figure was $48000.0, up 45.45% from the prior year.
- Current Leases rose to $48000.0 in Q4 2023 per RNTX's latest filing, from $33000.0 in the prior quarter.
- Across five years, Current Leases topped out at $512000.0 in Q3 2020 and bottomed at $33000.0 in Q4 2022.
- Historically, Current Leases has averaged $242875.0 across 5 years, with a median of $115500.0 in 2022.
- Annual changes were most pronounced in 2021 — Current Leases slumped 81.84% — and 2023, when it soared 45.45%.
- Rein Therapeutics' Current Leases stood at $446000.0 in 2019, then rose by 14.8% to $512000.0 in 2020, then plunged by 81.84% to $93000.0 in 2021, then slumped by 64.52% to $33000.0 in 2022, then jumped by 45.45% to $48000.0 in 2023.
- Business Quant data shows RNTX's Current Leases at $48000.0 in Q4 2023, $33000.0 in Q4 2022, and $67000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | - |
| 10 | Rein Therapeutics | 54.50 Mn | 54.50 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 48,000.00 |
| Dec 31, 2022 | 33,000.00 |
| Sep 30, 2022 | 67,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 131,000.00 |
| Dec 31, 2021 | 93,000.00 |
| Sep 30, 2021 | 93,000.00 |
| Jun 30, 2021 | 93,000.00 |
| Mar 31, 2021 | 93,000.00 |
| Sep 30, 2020 | 512,000.00 |
| Jun 30, 2020 | 490,000.00 |
| Mar 31, 2020 | 468,000.00 |
| Dec 31, 2019 | 446,000.00 |
| Sep 30, 2019 | 426,000.00 |
| Jun 30, 2019 | 406,000.00 |
| Mar 31, 2019 | 387,000.00 |